OXFORD BIOMEDICA PLC financials
OXFORD BIOMEDICA PLC
213800S1GVQNXQ15K851 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | £168.7M | £128.8M |
| Cost of sales | £102.8M | £75.8M |
| Gross profit | £66.0M | £53.0M |
| Other income | £1.1M | £3.5M |
| Administrative expenses | £36.8M | £29.4M |
| Operating profit (EBIT) | -£22.5M | -£39.4M |
| Finance costs | £14.6M | £11.1M |
| Profit before tax | -£31.9M | -£47.3M |
| Income tax expense | -£1.3M | £1.3M |
| Profit for the year | -£30.6M | -£48.6M |
| — attributable to owners | -£30.1M | -£43.2M |
| — attributable to NCI | -£517.0K | -£5.4M |
| Total comprehensive income | -£33.7M | -£49.3M |
| Per share | ||
| Basic EPS | £-0.27 | £-0.42 |
| Diluted EPS | £-0.27 | £-0.42 |
| Free cash flow / share | £-0.04 | £-0.50 |
| Cash flow statement | ||
| Cash generated from operations | -£4.6M | -£50.7M |
| Net cash from operating activities | £507.0K | -£50.7M |
| Net cash from investing activities | -£5.7M | £5.6M |
| Purchase of PP&E (capex) | £4.8M | £7.5M |
| Net cash from financing activities | £42.3M | £2.9M |
| Proceeds from borrowings | £42.0M | £0 |
| Repayments of borrowings | £38.8M | £466.0K |
| Net change in cash | £37.0M | -£42.1M |
| Balance sheet | ||
| Non-current assets | £140.1M | £98.4M |
| Intangible assets & goodwill | £25.2M | £29.2M |
| Current assets | £185.6M | £133.2M |
| Inventories | £17.3M | £13.6M |
| Trade & other receivables | £71.3M | £59.0M |
| Cash & equivalents | £96.9M | £60.6M |
| Total equity | £91.3M | £60.5M |
| — attributable to owners | £91.3M | £57.0M |
| Non-controlling interests | £0 | £3.4M |
| Non-current liabilities | £150.2M | £112.8M |
| Long-term borrowings | £41.5M | £39.8M |
| Lease liabilities (non-current) | £100.6M | £64.6M |
| Current liabilities | £84.2M | £58.3M |
| Lease liabilities (current) | £6.1M | £4.1M |
| Trade & other payables | £35.4M | £26.2M |
| Derived metrics | ||
| Free cash flow | -£4.3M | -£58.2M |
| Operating margin | -13.3% | -30.6% |
| Net margin | -18.2% | -37.7% |
| Return on equity | -33.5% | -80.4% |
| Cash conversion ratio | -0.02× | 1.04× |
| Capex coverage | 0.11× | -6.76× |
| Other reported items | ||
| Cash and Cash Equivalents If Different From Statement of Financial Position | £96.9M | £60.6M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £3.3M | -£9.0M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | £0 | £0 |
| Comprehensive Income Attributable To Noncontrolling Interests | -£517.0K | -£5.5M |
| Comprehensive Income Attributable To Owners of Parent | -£33.1M | -£43.9M |
| Current Assets Liabilities | £101.4M | £74.9M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | £0 | £281.0K |
| Current Contract Liabilities | £42.3M | £23.6M |
| Current Deferred Income Other Than Current Contract Liabilities | £472.0K | £562.0K |
| Current Derivative Financial Assets | £166.0K | £0 |
| Current Provisions | £0 | £1.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£810.0K | -£940.0K |
| Finance Income | £5.2M | £3.2M |
| Gain Recognised In Bargain Purchase Transaction | £9.9M | £1.7M |
| Gains Losses On Cash Flow Hedges Net of Tax | £147.0K | £0 |
| Income Taxes Paid Refund Classified As Operating Activities | -£5.1M | £0 |
| Increase Decrease Through Sharebased Payment Transactions | £4.7M | £2.1M |
| Increase Decrease Through Transactions With Owners | £62.6M | £24.9M |
| Interest Paid Classified As Financing Activities | £4.6M | £4.1M |
| Interest Received Classified As Investing Activities | £2.4M | £4.1M |
| Investments In Subsidiaries | £0 | £0 |
| Issued Capital | £60.4M | £53.0M |
| Net Assets Liabilities | £91.3M | £60.5M |
| Noncurrent Contract Liabilities | £85.0K | £50.0K |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | £606.0K | £1.0M |
| Noncurrent Provisions | £7.4M | £7.4M |
| Noncurrent Receivables | £7.3M | £4.9M |
| Other Comprehensive Income | -£3.0M | -£737.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -£3.2M | -£737.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation Other Than Translation of Foreign Operations | -£3.2M | -£737.0K |
| Other Expense By Function | £50.7M | £57.3M |
| Other Reserves | £7.5M | £8.7M |
| Payments From Changes In Ownership Interests In Subsidiaries | £2.0M | £0 |
| Proceeds From Issuing Shares | £58.1M | £17.5M |
| Property Plant and Equipment Including Rightofuse Assets | £107.6M | £64.3M |
| Purchase of Treasury Shares | £179.0K | — |
| Research and Development Expense | £5.1M | £4.5M |
| Retained Earnings | -£422.4M | -£399.5M |
| Share Premium | £445.8M | £394.9M |
Every line item above is a fact tagged in OXFORD BIOMEDICA PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.